First Aid Shot Therapy launches upset stomach remedy in shot format
SEATTLE — First Aid Shot Therapy on Wednesday announced the launch of First Aid Shot Therapy Upset Stomach. Upset Stomach is the second variant to be launched in the F.A.S.T. range of products and it is formulated to relieve upset stomach symptoms.
F.A.S.T. Upset Stomach Relief, contains calcium carbonate, an antacid that works by directly neutralizing stomach acid. To ensure a great-tasting formula, F.A.S.T. is formulated with natural peppermint and ginger flavors along with a hint of chocolate for smoothness. Upset Stomach helps relieve heartburn, sour stomach, acid indigestion and upset stomach associated with these symptoms that may be caused by stomach acid. Each 1.15 fl. oz. (34 ml) bottle is a single dose, and may be taken every 3-4 hours if symptoms persist.
“Feeling sick never comes at the right time; it’s usually while you’re least expecting it, not when you’re standing in front of your medicine cabinet,” stated Mary Page Platerink, CEO First Aid Shot Therapy. “With F.A.S.T. we’re able to provide people with a quick, simple, no-mess, single-dose of relief that allows them to manage their health in a convenient and innovative way.”
Earlier this year, First Aid Shot Therapy launched First Aid Shot Therapy Pain Relief. A single-dose, over the counter liquid shot that relieves pain. F.A.S.T. Pain Relief contains choline salicylate and caffeine.
Rite Aid realizes 0.4% March gain with sales of $1.9 billion
CAMP HILL, Pa. — Rite Aid on Thursday posted $1.9 billion in sales for the four weeks ended March 29, up 0.4%.
Same-store sales increased 0.7% over the prior-year period. March front-end same store sales decreased 5%, with 4.1% of the decrease attributable to a shift in the timing of Easter, which falls on April 20 this year compared to March 31 last year.
Pharmacy same-store sales, which included an approximate 133 basis points negative impact from new generic introductions, increased 3.5%. Prescription count at comparable stores increased 1.1% over the prior-year period.
Prescription sales accounted for 69.4% of drug store sales, and third party prescription sales represented 97.4% of pharmacy sales.
FDA advisory committees recommend approval of ultra rapid-acting mealtime insulin therapy
VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
If approved, AFREZZA would be the first ultra rapid-acting mealtime insulin therapy available in the United States.
"We are pleased with the Advisory Committee’s approval recommendation in support of Afrezza, and we appreciate the thoroughness of their review," stated Alfred Mann, chairman and CEO MannKind Corporation. "We look forward to working with the FDA as they complete their evaluation of Afrezza."